title: In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.
abstract: The BAX proapoptotic protein is capable of inducing cell death either directly, through its effects on mitochondrial function, or indirectly, by lowering the apoptotic threshold in response to certain chemotherapy agents. In this study, we tested the hypothesis that selective expression of BAX in human ovarian cancer through adenoviral gene transfer might represent a novel approach to eradicating tumor cells in vivo. Two constructs were prepared using replication-deficient adenoviral vectors containing either the cDNA for beta-galactosidase (Ad.DF3.betaGAL) or hemagglutinin (HA)-tagged BAX (Ad.DF3.BAX) under the control of the DF3 promoter. The DF3 promoter was used to confer tumor-specific gene expression in view of its restricted pattern of expression in the majority of human ovarian cancers and its limited expression in normal peritoneal mesothelial cells. In vitro infection of up to seven different epithelial cancer cell lines with Ad.DF3.betaGAL or Ad.DF3.BAX resulted in expression of either beta-galactosidase activity or HA-BAX protein, respectively, which was highly correlated with DF3 levels. Furthermore, infection with Ad.DF3.BAX was capable of highly selective cytotoxicity of DF3-positive ovarian cancer clonogenic cells in vitro. The effect of i.p. administration of Ad.DF3.BAX was also assessed in nude mice inoculated with the DF3-positive 36M2 human ovarian cancer cell line. Expression of either beta-galactosidase activity (after Ad.DF3.betaGAL treatment) or HA-BAX transcripts (after Ad.DF3.BAX treatment) was restricted to tumor tissue in vivo. Importantly, administration of Ad.DF3.BAX on days 2 and 3 after tumor inoculation was capable of eradicating >99% of tumor implants. These results demonstrate the feasibility of tumor selective expression of a proapoptotic protein such as BAX through adenoviral gene transfer.
authors.affiliation: Department of Adult Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02215, USA.
authors.forename: Y T
authors.initials: YT
authors.lastname: Tai
authors.forename: T
authors.initials: T
authors.lastname: Strobel
authors.forename: D
authors.initials: D
authors.lastname: Kufe
authors.forename: S A
authors.initials: SA
authors.lastname: Cannistra
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000260:Adenoviruses, Human / Q000235:genetics; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics*; D017209:Apoptosis / Q000235:genetics*; D001943:Breast Neoplasms / Q000473:pathology; D005240:Feasibility Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D006801:Humans; D007274:Injections, Intraperitoneal; D007763:Lac Operon; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D011401:Promoter Regions, Genetic; D011471:Prostatic Neoplasms / Q000473:pathology; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D019253:Proto-Oncogene Proteins c-bcl-2; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000378:metabolism; D051028:bcl-2-Associated X Protein; D001616:beta-Galactosidase / Q000032:analysis / Q000235:genetics
chemical_list: D000951:Antigens, Neoplasm; C494826:BAX protein, human; C494827:Bax protein, mouse; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011993:Recombinant Fusion Proteins; D051028:bcl-2-Associated X Protein; D001616:beta-Galactosidase